Vorinostat, a HDAC inhibitor used to treat cutaneous T-cell lymphoma (CTCL), has been reported to induce TdP in a 49-year-old African American man [50]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.